2020 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

The 2020 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline report presents a comprehensive overview of the research and development of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Pre-clinical phase and five drugs in Phase 1.

As of February 2020, the Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline remains robust with 8 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) treatment. Diverse types of targeted therapies are being explored through clinical trials including Cannabinoid receptor agonist; Cholesterol 24-hydroxylase inhibitor; enzyme farnesyl pyrophosphate synthase; NMDA receptor antagonist; Neuromuscular blocking agents; Opioid receptor agonist.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

Publisher Expertise

The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

Scope:

• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) development
• Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline candidates included
• Business overview and snapshot of all companies involved in Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline are included
• Latest market and pipeline developments are provided in the report

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) pipeline companies included in the report are: Allergan Plc, Bexson Biomedical Inc, Biohaven Pharmaceutical Holding Company Ltd, NeuroTherpia Inc, Piramal Enterprises Ltd, Takeda Pharmaceutical Co Ltd, Tetra Bio-Pharma Inc, Thar Pharmaceuticals.

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) pipeline drugs profiled in the report include: BHV-5000, onabotulinumtoxinA, ketamine, T-121, NTRX-07, hydromorphone intrathecal, soticlestat (TAK-935), PPP001.